Transdermal Drug Delivery System Market Size, Share & Industry Analysis, By Type (Patches, Gels), By Application (Pain Management, Cardiovascular Diseases, Central Nervous System Diseases, Others), By End User (Hospitals, Clinics, Home Care Settings, Others) and Regional Forecast, 2024-2032

Transdermal drug delivery system (TDDS) is one of the systems categorized under the controlled drug delivery, where drugs are delivered through the skin at a predetermined and controlled rate. These systems are used for treating various disease conditions such as cardiovascular disorders, and central nervous system disorders, etc. Drugs administered through skin patches include scopolamine (for motion sickness), nicotine (for quitting smoking), nitro-glycerine (for angina), and lidocaine to relieve the pain of shingles (herpes zoster). These devices have various advantages, like prolonged therapeutic effect, reduced side-effects, improved bioavailability, better patient compliance and easy termination of drug therapy. There are three main routes of drug penetration, which include the appendageal, transcellular and intercellular routes.

Growing geriatric population and the rise of several chronic diseases such as orthopedic diseases, and other disorders among the elderly population is fuelling the demand for transdermal drug delivery patches. In addition, transdermal drug delivery system offers several benefits such as enhanced safety, efficacy, and reduced inter-patient variability of doses. These are some of the factors favouring transdermal drug delivery systems market growth.

However, high cost of transdermal patches in comparison to other conventional treatment methods and low adoption in emerging markets restrains the growth of the transdermal drug delivery systems market

Key Players Covered:

Some of the major companies that are present in the transdermal drug delivery system market are 3M, Mylan, Lubrizol Corporation, AdhexPharma, DuPont, Novartis AG, Endo International, Purdue Pharma L.P., and others.

Pain management segment is anticipated to hold the largest market share in transdermal drug delivery system devices in the forecast period. Higher adoption of opioid medication patches in pain management, especially among cancer patients, is one of the major factors propelling the growth of the segment in the global market.

Key Insights

• New Product Launches, Key Players, 2018


• Technological Advancements in TDDS


• Recent Industry Developments Such as Partnerships, Mergers, And Acquisitions

Regional Analysis:

North America dominated the global transdermal drug delivery system devices market in 2018, and is projected to continue its dominance during the forecast period. Major factors attributed to the dominance include, rising prevalence of disorders such as, chronic pain, cardiovascular diseases, and central nervous system diseases, along with research activities being conducted by market players to introduce new products in the region. The Asia Pacific transdermal drug delivery system market is projected to register the comparatively higher growth rate in the forecast period.

Rising healthcare expenditure, growing healthcare awareness, and rising investments by various players operating in the region for the development of novel patches, are some of the factors driving the growth of the transdermal drug delivery systems in the region. Latin America and Middle East & Africa are projected to grow at a moderate CAGR during the forecast period.

Segmentation

Key Industry Developments

• In September 2019, Nemaura Pharma entered into a strategic collaboration with Sparsha Pharma USA for development and manufacturing of transdermal drug delivery systems.


• In December 2016, Luye pharma group Ltd announced the completion of its acquisitions of transdermal drug delivery system business from Swiss company, Acino